Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
Positive surprises with Lexicon’s Zynquista and DBV’s Viaskin Peanut show that you can never entirely write biotech off.
Myovant and Pfizer showed that deal-making was not taking a Christmas break, but for Celgene CVR holders the dream is almost over. And vaccine approvals gained pace.
An extraordinary meeting of the EU CHMP recommends conditional approval of Pfizer/Biontech’s Covid-19 vaccine.
It is vital that the first authorised at-home, non-prescription Covid-19 antigen test be used in the right way.
As Biontech and Pfizer’s Covid-19 vaccine gets a positive US vote, delays for Sanofi, Glaxo and CSL show that top-speed drug development is the exception.
Digital therapeutics are going from strength to strength during the pandemic.
The UK’s swift authorisation of Biontech and Pfizer’s Covid-19 shot has attracted both praise and concern.
The need for another pivotal trial of omaveloxolone in Friedreich's ataxia looks increasingly likely.